Oligomer-Opioid Conjugates for Reduced CNS Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid agonists used for pain management are associated with potential abuse, significant first-pass metabolism, and CNS-mediated effects such as slowed breathing, which can be fatal, limiting their therapeutic desirability.
Innovation Solution
Development of chemically modified opioid agonists conjugated with water-soluble, non-peptidic oligomers, specifically attaching opioid agonists like nalbuphine to PEG chains via stable linkages, reducing affinity for metabolizing substrates and the blood-brain barrier, thereby minimizing metabolism and CNS effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid agonists are administered for pain management, then analgesic effect is achieved, but potential for abuse and CNS-mediated effects (slowed breathing) increase
Solution Approach 1:
The patent applies the intermediary principle by conjugating opioid agonists with water-soluble oligomers (such as PEG chains). This oligomer conjugate acts as an intermediary structure that modifies the pharmacokinetic properties of the opioid agonist. The conjugate reduces penetration through the blood-brain barrier while maintaining peripheral analgesic activity, thereby decreasing CNS-mediated harmful effects and abuse potential while preserving therapeutic benefits
Solution Approach 2:
The patent employs parameter changes by modifying the molecular properties of opioid agonists through conjugation with oligomers. This changes key parameters including water solubility, molecular size, and blood-brain barrier permeability. The conjugation alters the pharmacokinetic profile to reduce CNS penetration and metabolism while maintaining analgesic efficacy at peripheral sites
2Ease of operation
If opioid agonists are administered orally, then convenience of administration is improved, but first pass metabolism increases
Solution Approach 1:
The water-soluble oligomer conjugate serves as an intermediary that protects the opioid agonist from rapid first-pass metabolism. The conjugate structure modifies hepatic metabolism kinetics, allowing for more predictable and sustained systemic availability after oral administration, thereby reducing the loss of active substance while maintaining administration convenience
3Object-affected harmful factors
If opioid agonists are modified to reduce CNS penetration, then harmful CNS effects are reduced, but analgesic efficacy may be compromised
Solution Approach 1:
The patent applies local quality by creating a conjugate that selectively targets peripheral pain sites while limiting CNS penetration. The oligomer-conjugated opioid agonist maintains high affinity for peripheral opioid receptors at the site of pain (local action) while the conjugate structure physically limits access to the central nervous system. This achieves localized analgesic effect with reduced CNS-mediated harmful effects
Solution Approach 2:
The conjugation modifies physical-chemical parameters of the opioid agonist, particularly molecular size and hydrophilicity, to create a size-exclusion effect at the blood-brain barrier. This parameter change allows the conjugate to maintain peripheral analgesic activity while selectively reducing CNS penetration, preserving therapeutic efficacy while minimizing harmful central effects
Data Source
AI summary
The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.